Maker of much-debated ALS drug says it may stop selling it after study showed it didn't work
by Matthew Perrone
Mar 08, 2024
2 minutes
The maker of a much-debated drug for Lou Gehrig’s disease said Friday its therapy failed to help patients in a large follow-up study, but stopped short of committing to follow through on a prior pledge to pull the drug from the U.S. market.
The Food and Drug Administration approved Amylyx Pharmaceuticals’ Relyvrio in September 2022, following a, a fatal muscle-wasting disease.
You’re reading a preview, subscribe to read more.
Start your free 30 days